← Back to Clinical Trials
Recruiting NCT05562375

NCT05562375 Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05562375
Status Recruiting
Phase
Sponsor Universidad Rey Juan Carlos
Condition Oral Potentially Malignant Disorders
Study Type INTERVENTIONAL
Enrollment 73 participants
Start Date 2022-01-08
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
GOCCLESToluidine blue stainBiopsy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 73 participants in total. It began in 2022-01-08 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Oral potentially malignant disorders (OPMDs) are chronic pathologies which can suffer dysplastic alterations and evolve into oral cancer. The diagnosis of those pathologies is commonly done by visual inspection, which is not capable of determining the presence or not of dysplasia. Furthermore, this type of diagnosis depends greatly on the expertise and training of the professional. In recent years, new methods that can help early oral cancer diagnosis have been developed. A new device has been commercialized, named GOCCLES® (Glasses for Oral Cancer Curing Light Exposed Screening), based on the autofluorescence principle. The hypothesis of this study is that GOCCLES® device could be an effective tool to help in early detection of oral cancer.

Eligibility Criteria

Inclusion Criteria: * Patients older than 18. * Patients that present oral mucosa injuries compatible with OPMD. * Patients that understand the purpose of the study and express consent Exclusion Criteria: * Patients that don't have the capability to express consent. * Patients with systemic pathologies that contraindicate a biopsy. * Patients with a recent biopsy at the oral cavity

Contact & Investigator

Central Contact

Rocío Teresa Martín Muñoz

✉ rt.martin@alumnos.urjc.es

📞 645468417

Principal Investigator

Rocío Teresa Martín Muñoz

PRINCIPAL INVESTIGATOR

Universidad Rey Juan Carlos de Madrid

Frequently Asked Questions

Who can join the NCT05562375 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Oral Potentially Malignant Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05562375 currently recruiting?

Yes, NCT05562375 is actively recruiting participants. Contact the research team at rt.martin@alumnos.urjc.es for enrollment information.

Where is the NCT05562375 trial being conducted?

This trial is being conducted at Alcorcón, Spain.

Who is sponsoring the NCT05562375 clinical trial?

NCT05562375 is sponsored by Universidad Rey Juan Carlos. The principal investigator is Rocío Teresa Martín Muñoz at Universidad Rey Juan Carlos de Madrid. The trial plans to enroll 73 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology